Sage Therapeutics’ SAGE-217 fails in late-stage depression trial

Sage Therapeutics is developing SAGE-217 for the treatment of depression. Credit: ryan melaugh.



  • Sage Therapeutics’ SAGE-217 fails in late-stage depression trial